Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres

Adjuvant chemotherapy for Stage II colon cancer offers a small (2-3%) overall survival benefit and is not universally recommended. Mismatch repair deficiency (dMMR) confers an improved prognosis identifying patients unlikely to benefit from adjuvant chemotherapy. The aim of this study was to investigate the use of dMMR immunohistochemistry in two major cancer treatment centres.

Source: International Journal of Surgery - January 21, 2018 Category: Surgery Authors: Matthew Grant, Andrew Haydon, Lewis Au, Simon Wilkins, Karen Oliva, Eva Segelov, Yoland Antill, Peter Carne, Pravin Ranchod, Adrian Polglase, Chip Farmer, Martin Chin, Roger Wale, Paul Simpson, Stephen Bell, Stewart Skinner, Paul McMurrick, Jeremy Shapiro Tags: Original Research Source Type: research